Finance

Lists
Why is YP2 down 2,31%?
Dive Deeper
YP2:FRA
BioLine RX Ltd - ADR
1,69 €
-2,31%
(-0,040) 1D
20 հոկ, 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for YP2...
Open
1,51 €
High
1,69 €
Low
1,51 €
Mkt. cap
11,86 մլն
Avg. vol.
41,00
Volume
0,00
52-wk high
3,26 €
52-wk low
1,51 €
No. of employees
22
Open
1,51 €
High
1,69 €
Low
1,51 €
Mkt. cap
11,86 մլն
Avg. vol.
41,00
Volume
0,00
52-wk high
3,26 €
52-wk low
1,51 €
No. of employees
22
News stories
From web sources and news partners
Profile
BioLineRx Ltd., or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Wikipedia
About BioLine RX Ltd - ADR
CEOPhilip A. Serlin
Employees22
Founded2003
Headquarters-
Sector-
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
427,00 հզր
194,00 հզր
477,00 հզր
294,00 հզր
Cost of goods sold
84,00 հզր
40,00 հզր
95,00 հզր
59,00 հզր
Cost of revenue
84,00 հզր
40,00 հզր
95,00 հզր
59,00 հզր
Research and development expenses
1,72 մլն
2,42 մլն
2,53 մլն
2,94 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
831,00 հզր
1,12 մլն
858,00 հզր
865,00 հզր
Operating expense
2,55 մլն
3,54 մլն
3,39 մլն
3,81 մլն
Total operating expenses
2,63 մլն
3,58 մլն
3,48 մլն
3,87 մլն
Operating income
-2,21 մլն
-3,39 մլն
-3,00 մլն
-3,57 մլն
Other non operating income
1,16 մլն
1,10 մլն
458,00 հզր
-690,00 հզր
EBT including unusual items
-977,00 հզր
-2,24 մլն
-2,59 մլն
-4,34 մլն
EBT excluding unusual items
-977,00 հզր
-2,24 մլն
-2,59 մլն
-4,34 մլն
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-977,00 հզր
-1,38 մլն
-1,60 մլն
-3,03 մլն
Net profit margin
-228,81%
-713,92%
-335,64%
-1 029,25%
Earnings per share
-
-
-
-
Interest and investment income
377,00 հզր
-
208,00 հզր
132,00 հզր
Interest expense
-304,00 հզր
-288,00 հզր
-250,00 հզր
-208,00 հզր
Net interest expenses
73,00 հզր
-288,00 հզր
-42,00 հզր
-76,00 հզր
Depreciation and amortization charges
-
-
-
-
EBITDA
-2,09 մլն
-3,33 մլն
-2,92 մլն
-3,50 մլն
Gain or loss from assets sale
-
25,00 հզր
-
-
AI content may include mistakes. Learn more
Google Apps